Subject
Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine
Reference33 articles.
1. Incremental cost-effectiveness of 13-valent pneumococcal conjugate vaccine for adults age 50 years and older in the United States;Stoecker;J Gen Intern Med,2016
2. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the advisory committee on immunization practices (ACIP);Tomczyk;MMWR Morb Mortal Wkly Rep,2014
3. Pilishvili T, Gierke R, Xing W, Farley M, Schaffner W, Thomas A, et al. Impact of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) use on Invasive Pneumococcal Disease (IPD) Among Adults in the United States. ISPPD Abstract 0696. 2018.
4. Palisade Corporation. @Risk 5.7. Newfield, NY2011.
5. Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcalpolysaccharide vaccine to adults with immunocompromising conditions;Cho;Vaccine,2013
Cited by
31 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献